Journal of Thrombosis and Haemostasis

Van Creveld, pioneer of hemophilia care and coagulation research in the Netherlands: a personal account
pp. 1029-1033(5)
Author: Van Mourik J.A.

Long-term low-dose warfarin use is effective in the prevention of recurrent venous thromboembolism: yes
pp. 1034-1037(4)
Author: Ridker P.M.

Long-term low-dose warfarin use is effective in the prevention of recurrent venous thromboembolism: no
pp. 1038-1040(3)
Author: Agnelli G.

Long-term low-dose warfarin use is effective in the prevention of recurrent venous thromboembolism: no
pp. 1041-1043(3)
Author: Kovacs M.J.

In praise of long-term prospective data collection: questions and perspectives
pp. 1044-1046(3)
Author: Dimichele D.

The incidence of factor VIII and factor IX inhibitors in the hemophilia population of the UK and their effect on subsequent mortality, 1977–99
pp. 1047-1054(8)
Authors: Darby S.C.; Keeling D.M.; Spooner R.J.D.; Wan Kan S.; Giangrande P.L.F.; Collins P.W.; Hill F.G.H.; Hay C.R.M.

Prevention of venous thromboembolism after major orthopedic surgery: summing up evidence about old and new antithrombotic agents
pp. 1055-1057(3)
Author: Iorio A.

Prevention of venous thromboembolism in orthopedic surgery with vitamin K antagonists: a meta-analysis
pp. 1058-1070(13)
Authors: Mismetti P.; Laporte S.; Zufferey P.; Epinat M.; Decousus H.; Cucherat M.

Antiphospholipid antibodies: do we still need to perform anticardiolipin ELISA assays?
pp. 1071-1073(3)
Authors: De Moerloose P.; Reber G.

Should our approach to the anticardiolipin assay change 20 years after its discovery?
pp. 1074-1076(3)
Authors: Meroni P.L.; Tincani A.

The anticardiolipin assay is required for sensitive screening for antiphospholipid antibodies
pp. 1077-1081(5)
Authors: Nash M.J.; Camilleri R.S.; Kunka S.; Mackie I.J.; Machin S.J.; Cohen H.

Pathogenic antibodies to coagulation factors. Part one: Factor VIII and Factor IX
pp. 1082-1095(14)
Author: Lollar P.

Prophylactic and therapeutic recombinant factor VIIa administration to patients with Glanzmann's thrombasthenia: results of an international survey
pp. 1096-1103(8)
Authors: Poon M-C.; D'Oiron R.; Von Depka M.; Khair K.; Négrier C.; Karafoulidou A.; Huth-Kuehne A.; Morfini M.

Non-fatal major bleeding during treatment with vitamin K antagonists: influence of soluble thrombomodulin and mutations in the propeptide of coagulation factor IX
pp. 1104-1109(6)
Authors: Van Der Heijden J.F.; Rekké B.; Hutten B.A.; Van Der Meer F.J.M.; Remkes M.G.H.; Vermeulen M.; Büller H.R.; Reitsma P.H.

Non-invasive diagnostic work-up of patients with clinically suspected pulmonary embolism; results of a management study
pp. 1110-1117(8)
Authors: Ten Wolde M.; Hagen P.J.; Macgillavry M.R.; Pollen I.J.; Mairuhu A.T.A.; Koopman M.M.W.; Prins M.H.; Hoekstra O.S.; Brandjes D.P.M.; Postmus P.E.; Büller H.R.

Circulating procoagulant microparticles and soluble GPV in myocardial infarction treated by primary percutaneous transluminal coronary angioplasty. A possible role for GPIIb-IIIa antagonists
pp. 1118-1126(9)
Authors: Morel O.; Hugel B.; Jesel L.; Mallat Z.; Lanza F.; Douchet M-P.; Zupan M.; Chauvin M.; Cazenave J-P.; Tedgui A.; Freyssinet J-M.; Toti F.

Role of the -carboxyglutamic acid domain of activated factor X in the presence of calcium during inhibition by antithrombin–heparin
pp. 1127-1134(8)
Authors: Whinna H.C.; Lesesky E.B.; Monroe D.M.; High K.A.; Larson P.J.; Church F.C.

A novel type 2A (Group II) von Willebrand disease mutation (L1503Q) associated with loss of the highest molecular weight von Willebrand factor multimers
pp. 1135-1142(8)
Authors: O'Brien L.A.; Sutherland J.J.; Hegadorn C.; Benford K.; Racz H.; Rapson D.; Hough C.; Lillicrap D.

Two novel mutations in EGF-like domains of human factor IX dramatically impair intracellular processing and secretion
pp. 1143-1154(12)
Authors: Enjolras N.; Plantier J-L.; Rodriguez M-H.; Rea M.; Attali O.; Vinciguerra C.; Negrier C.

Rapid and efficient incorporation of tissue factor into liposomes
pp. 1155-1162(8)
Authors: Smith S.A.; Morrissey J.H.

Enhancement of enzymatic fibrinolysis with 2-MHz ultrasound and microbubbles
pp. 1163-1166(4)
Authors: Cintas P.; Nguyen F.; Boneu B.; Larrue V.

A novel Phe171Cys mutation in integrin _IIb causes Glanzmann thrombasthenia by abrogating _IIb3 complex formation
pp. 1167-1175(9)
Authors: Rosenberg N.; Landau M.; Luboshitz J.; Rechavi G.; Seligsohn U.

Aspirin inhibits endothelial cell activation induced by antiphospholipid antibodies
pp. 1176-1181(6)
Authors: Dunoyer-Geindre S.; Kruithof E.K.O.; Boehlen F.; Satta-Poschung N.; Reber G.; de Moerloose P.

Antithrombotic prophylaxis for women with thrombophilia and pregnancy complications
pp. 1182-1183(2)
Authors: Zotz R.B.; Gerhardt A.; Scharf R.E.

Antithrombotic prophylaxis for women with thrombophilia and pregnancy complications
pp. 1183-1184(2)
Author: Brenner B.

Antithrombotic prophylaxis for women with thrombophilia and pregnancy complications
pp. 1184-1185(2)
Author: Martinelli I.

Antithrombotic prophylaxis for women with thrombophilia and pregnancy complications
pp. 1185-1186(2)
Author: Walker I.D.

Antithrombotic prophylaxis for women with thrombophilia and pregnancy complications
pp. 1187-1188(2)
Authors: Grandone E.; Margaglione M.

Antithrombotic prophylaxis for women with thrombophilia and pregnancy complications
pp. 1188-1189(2)
Authors: Wells P.S.; Rodger M.A.

Antithrombotic prophylaxis in women with thrombophilia and pregnancy complications
pp. 1190-1192(3)
Author: Conard J.

Screening for thrombophilia in children: a puzzling decision with unclear implications
pp. 1193-1194(2)
Authors: Tormene D.; Pagnan A.; Prandoni P.; Simioni P.

Does heparin therapy improve pregnancy outcome in patients with thrombophilias?
pp. 1194-1195(2)
Authors: Paidas M.; Ku D.-H.; Triche E.; Lockwood C.; Arkel Y.

Association between the acquired free protein S deficiency in HIV-infected patients with the lipid profile levels
pp. 1195-1197(3)
Authors: De Larrañaga G.; Perés S.; Puga L.; Alonso B.; Benetucci J.

Protein Z gene polymorphisms are associated with protein Z plasma levels
pp. 1197-1199(3)
Authors: Santacroce R.; Cappucci F.; Di Perna P.; Sessa F.; Margaglione M.

Tissue factor expression and P2Y₁₂ gene polymorphism
pp. 1199-1200(2)
Authors: Reny J-L.; Gaussem P.; Remones V.; Emmerich J.; Fontana P.

Treatment of patients initially for acute deep vein thrombosis with a low-molecular-weight heparin at a fixed, body weight-independent dosage
pp. 1200-1202(3)
Authors: Harenberg J.; Riess H.; Brom J.; Weidinger G.

Establishing a normal range ford-dimer levels through pregnancy to aid in the diagnosis of pulmonary embolism and deep vein thrombosis
pp. 1202-1204(3)
Author: Morse M.

Observer variability in the assessment of clinical probability in patients with suspected pulmonary embolism
pp. 1204-1206(3)
Authors: Leclercq M.G.L.; Kruip M.J.H.A.; Mac Gillavry M.R.; Van Marwijk Kooy M.; Büller H.R.

Effect of age on the assessment of clinical probability of pulmonary embolism by prediction rules
pp. 1206-1208(3)
Authors: Righini M.; Le Gal G.; Perrier A.; Bounameaux H.

Potassium homeostasis in patients receiving prophylactic dose enoxaparin therapy
pp. 1208-1209(2)
Authors: Potti A.; Danielson B.; Badreddine R.; Ortel T.

Search for red blood cell cytoskeleton abnormalities in patients with venous thrombosis
pp. 1209-1210(2)
Authors: Chariout S.; Ffrench P.; Hanss M.

Prothrombin G20210A mutation, and not factor V Leiden mutation, is a risk factor for cerebral venous thrombosis in Brazilian patients
pp. 1211-1212(2)
Authors: Rodrigues C.A.; Rocha L.K.A.; Morelli V.M.; Franco R.F.; Lourenço D.M.

Hyperhomocysteinemia and severity of peripheral vascular disease: a rebuttal
pp. 1212-1213(2)
Authors: Haltmayer M.; Mueller T.; Poelz W.

Hyperchomocysteinemia and severity of peripheral vascular disease: reply to a rebuttal
pp. 1214-1214(1)
Authors: Ciccarone E.; Salcuni N.B.; Donati M.B.; Iacoviello L.

More on: cellular microparticles: what are they bad or good for?
pp. 1215-1216(2)
Authors: Ahn Y.S.; Jy W.; Jimenez J.J.; Horstman L.L.

Aspirin and platelet function
pp. 1216-1218(3)
Author: Breddin H.K.

Ilsley Ingram
pp. 1219-1219(1)
Author: Mannucci P.M.

TALKING ABOUT…
pp. 1220-1222(3)
Authors: Bruttomesso G.; Miglino N.

ANNOUNCEMENTS
pp. 1223-1223(1)

Erratum
pp. 1224-1224(1)